New Study Finds HCQ Increases Covid-19 Patients Survival Rate by 200%, Lancet Study Which Raised Doubts Over HCQ’s Efficacy Was Later Withdrawn

Then US President Donald Trump had batted for HCQ but WHO had sabotaged the study about efficacy of HCQ.

A new study has found HCQ (Hydroxychloroquine) increases the survival rate of severely infected Covid-19 patients by 200%.

After the effectiveness of the HCQ was talked about in the very beginning of the pandemic, India has banned its export.

India manufactures more than 70 percent of the global HCQ. Indian pharmaceutical companies IPCA Laboratories, Zydus Cadila and Wallace Pharmaceuticals have major shares.

Then US President Donald Trump had dialled Prime Minister Narendra Modi for supply of HCQ.

A study published in the medical journal Lancet had said HCQ was not effective against SARS-COV-2, the virus that causes Covid-19.

In June last year, Lancet retracted that study as it was found to be fake and fabricated.

The study was conducted by St Barnabas Medical Center in New Jersey and the result was published on May 31.

HCQ, an antimalarial drug, is very commonly used for the treatment of autoimmune diseases.

The WHO has lost its credibility as it’s slowly emerging it was complicit with China in hiding information about the pandemic and wreaking havoc.